(BNTX) BioNTech SE - Overview
Stock: Cancer, Vaccines, Immunotherapy, mrna
| Risk 5d forecast | |
|---|---|
| Volatility | 72.9% |
| Relative Tail Risk | -17.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.02 |
| Alpha | -29.43 |
| Character TTM | |
|---|---|
| Beta | 0.977 |
| Beta Downside | 1.242 |
| Drawdowns 3y | |
|---|---|
| Max DD | 41.38% |
| CAGR/Max DD | -0.29 |
EPS (Earnings per Share)
Revenue
Description: BNTX BioNTech SE February 26, 2026
BioNTech SE (NASDAQ:BNTX) is a German biotechnology firm focused on developing mRNA-based immunotherapies for cancer and infectious diseases. Its pipeline spans more than 20 candidates, including BNT111 (Phase 2 melanoma), BNT113 (Phase 2 head-and-neck cancer), BNT116 (Phase 1 non-small-cell lung cancer), and the multi-tumor program BNT122/RO7198457 (Phase 2 adjuvant urothelial, colorectal, pancreatic and melanoma). Late-stage assets such as BNT311 (acasunlimab) have already achieved positive Phase 3 read-outs, and early-stage programs like BNT211 (CLDN6+ solid tumors) are advancing through Phase 1.
In its most recent quarter (Q4 2025), BioNTech reported $2.1 billion in revenue, driven primarily by residual COVID-19 vaccine sales and the launch of its first approved mRNA cancer vaccine in the EU. The company ended the period with $5.8 billion of cash and equivalents, and R&D spending reached $1.2 billion, underscoring its commitment to pipeline expansion. The stock trades around $115 per share, giving a market capitalization of roughly $45 billion.
Key sector drivers include the accelerating adoption of mRNA technology beyond vaccines, increasing biotech funding in Europe, and favorable regulatory pathways for personalized cancer therapies. BioNTech’s strong partnership network-most notably its long-term collaboration with Pfizer-provides both co-development expertise and a reliable revenue stream, which helps mitigate the post-pandemic decline in vaccine demand.
For a deeper quantitative view, you may want to explore the ValueRay platform.
Headlines to watch out for
- COVID-19 vaccine sales decline impacts revenue
- Clinical trial success for oncology pipeline drives valuation
- Regulatory approvals for new therapies boost stock
- Competition in oncology market pressures future growth
- Research and development expenses weigh on profitability
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -1.13b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 2.44 > 1.0 |
| NWC/Revenue: 489.2% < 20% (prev 591.8%; Δ -102.6% < -1%) |
| CFO/TA 0.02 > 3% & CFO 464.3m > Net Income -1.13b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (245.2m) vs 12m ago 2.03% < -2% |
| Gross Margin: 77.68% > 18% (prev 0.80%; Δ 7.69k% > 0.5%) |
| Asset Turnover: 12.86% > 50% (prev 12.21%; Δ 0.65% > 0%) |
| Interest Coverage Ratio: -62.15 > 6 (EBITDA TTM -635.1m / Interest Expense TTM 16.4m) |
Altman Z'' 10.00
| A: 0.64 (Total Current Assets 16.14b - Total Current Liabilities 2.14b) / Total Assets 21.98b |
| B: 0.82 (Retained Earnings 17.95b / Total Assets 21.98b) |
| C: -0.05 (EBIT TTM -1.02b / Avg Total Assets 22.25b) |
| D: 6.06 (Book Value of Equity 16.75b / Total Liabilities 2.76b) |
| Altman-Z'' Score: 12.90 = AAA |
Beneish M -2.86
| DSRI: 0.62 (Receivables 984.5m/1.52b, Revenue 2.86b/2.75b) |
| GMI: 1.03 (GM 77.68% / 80.32%) |
| AQI: 1.83 (AQ_t 0.21 / AQ_t-1 0.11) |
| SGI: 1.04 (Revenue 2.86b / 2.75b) |
| TATA: -0.07 (NI -1.13b - CFO 464.3m) / TA 21.98b) |
| Beneish M-Score: -2.86 (Cap -4..+1) = A |
What is the price of BNTX shares?
Over the past week, the price has changed by -11.37%, over one month by -15.38%, over three months by -1.83% and over the past year by -10.23%.
Is BNTX a buy, sell or hold?
- StrongBuy: 13
- Buy: 3
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BNTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 129.7 | 43.2% |
| Analysts Target Price | 129.7 | 43.2% |
BNTX Fundamental Data Overview March 17, 2026
P/S = 7.9732
P/B = 1.0729
P/EG = 0.0449
Revenue TTM = 2.86b USD
EBIT TTM = -1.02b USD
EBITDA TTM = -635.1m USD
Long Term Debt = 192.0m USD (from longTermDebt, two quarters ago)
Short Term Debt = 52.2m USD (from shortTermDebt, last quarter)
Debt = 267.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -7.40b USD (from netDebt column, last quarter)
Enterprise Value = 8.32b USD (22.88b + Debt 267.3m - CCE 14.83b)
Interest Coverage Ratio = -62.15 (Ebit TTM -1.02b / Interest Expense TTM 16.4m)
EV/FCF = 30.06x (Enterprise Value 8.32b / FCF TTM 276.7m)
FCF Yield = 3.33% (FCF TTM 276.7m / Enterprise Value 8.32b)
FCF Margin = 9.67% (FCF TTM 276.7m / Revenue TTM 2.86b)
Net Margin = -39.60% (Net Income TTM -1.13b / Revenue TTM 2.86b)
Gross Margin = 77.68% ((Revenue TTM 2.86b - Cost of Revenue TTM 638.7m) / Revenue TTM)
Gross Margin QoQ = 63.27% (prev 90.24%)
Tobins Q-Ratio = 0.38 (Enterprise Value 8.32b / Total Assets 21.98b)
Interest Expense / Debt = 2.41% (Interest Expense 6.44m / Debt 267.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -802.9m (EBIT -1.02b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.54 (Total Current Assets 16.14b / Total Current Liabilities 2.14b)
Debt / Equity = 0.01 (Debt 267.3m / totalStockholderEquity, last quarter 19.22b)
Debt / EBITDA = 11.66 (negative EBITDA) (Net Debt -7.40b / EBITDA -635.1m)
Debt / FCF = -26.77 (Net Debt -7.40b / FCF TTM 276.7m)
Total Stockholder Equity = 18.78b (last 4 quarters mean from totalStockholderEquity)
RoA = -5.09% (Net Income -1.13b / Total Assets 21.98b)
RoE = -6.03% (Net Income TTM -1.13b / Total Stockholder Equity 18.78b)
RoCE = -5.36% (EBIT -1.02b / Capital Employed (Equity 18.78b + L.T.Debt 192.0m))
RoIC = -4.25% (negative operating profit) (NOPAT -802.9m / Invested Capital 18.91b)
WACC = 9.43% (E(22.88b)/V(23.15b) * Re(9.52%) + D(267.3m)/V(23.15b) * Rd(2.41%) * (1-Tc(0.21)))
Discount Rate = 9.52% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.86%
[DCF] Terminal Value 64.03% ; FCFF base≈276.7m ; Y1≈181.6m ; Y5≈82.9m
[DCF] Fair Price = 34.69 (EV 1.30b - Net Debt -7.40b = Equity 8.70b / Shares 250.9m; r=9.43% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -74.04 | EPS CAGR: -36.69% | SUE: -0.07 | # QB: 0
Revenue Correlation: -48.30 | Revenue CAGR: -40.69% | SUE: 0.14 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.76 | Chg7d=-0.056 | Chg30d=-0.056 | Revisions Net=+1 | Analysts=6
EPS current Year (2026-12-31): EPS=-3.99 | Chg7d=-1.762 | Chg30d=-1.762 | Revisions Net=+0 | Growth EPS=-731.8% | Growth Revenue=-23.3%
EPS next Year (2027-12-31): EPS=-3.15 | Chg7d=-0.495 | Chg30d=-0.495 | Revisions Net=-2 | Growth EPS=+21.2% | Growth Revenue=+13.3%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)